Why Ozempic Costs What It Costs

Here is a small fact about Ozempic: in 2024, according to DrugPatentWatch, “the 2024 list price of Ozempic was $959 per 30-day supply in the United States.” That is the number most people are looking for when they type “ozempic price” into a search bar, and it is real in the sense that it is written down. It is less real in the sense that it is not obviously what anyone in particular pays.

The plain answer goes like this. The sticker was $959 a month. Brand-name Ozempic or Wegovy without insurance is quoted at $935 to $1,349 a month. Medicare’s negotiated price, starting January 1, 2027, is $274. Novo Nordisk’s own self-pay pen for Wegovy (same molecule, different box) starts at $199 a month. What insurers and the companies that manage drug benefits for them actually pay, after the money that flows back from the manufacturer, is not in any source I have. That number is the real price, and it is the one nobody prints.

What the Ozempic price on the sticker actually says

Let’s read that DrugPatentWatch sentence slowly, the way a lawyer reads a contract they are being paid by the hour to read (a job I would take, frankly).

“The 2024.” The price has a year attached. This is the first clue that it is not a fact about the drug. Semaglutide is the same molecule in 2024 as it is in 2027, when Medicare pays $274 for it. The molecule did not get 71% cheaper to make. The year changed and a law got involved.

“List price.” Not “price.” A list price is the price on the list. There are other prices. They are not on the list.

“Of Ozempic.” Of Ozempic specifically, not of semaglutide. Novo Nordisk sells the same active ingredient as Ozempic, Wegovy and Rybelsus, and they have different prices, because they are different products in the sense that matters, which is the commercial sense.

“Was $959.” Was. Past tense. Fine.

“Per 30-day supply.” Here I feel like the sentence is being honest with us. It is not per pen or per milligram. It is per month of being on the drug, which is how patients experience the cost, and also how a subscription works.

“In the United States.” This clause is doing a lot of work. In India the same company cut the price of Ozempic by 36% about ten days after generics showed up in March 2026. The price is a fact about a country, a year and a competitive situation. It is not a fact about the medicine.

So read literally, the sentence says: in one country, in one year, on one list, this was the number. Which is true. It is just very carefully not saying anything else.

Who pays the list price, basically

Here is the mechanism in plain words. The manufacturer announces a high price. Then a large buyer (an insurer, or the company that runs drug benefits for an employer’s health plan) says it would like to pay less. The manufacturer says fine, but you pay the high price at the pharmacy counter, and later I will send you a check for part of it, provided you put my drug on your list of covered drugs and make it easy to get. The buyer agrees. Everybody reports the high number in public and settles up in private.

The official name for the check is a rebate. The companies in the middle are pharmacy benefit managers, or PBMs. The list of covered drugs is a formulary (a word that sounds much calmer than the fights about it).

I mean, you can see the appeal. Imagine a meeting at a PBM, invented by me for illustration:

“Hey guys, Novo raised the list price.”

“Great, what’s the rebate?”

“Bigger.”

“Great.”

That meeting is made up. The incentive it describes is the general structure of the business: if a middleman’s compensation is tied to the size of the discount it extracts, then a higher starting price makes for a bigger, more impressive discount. On the other hand, nobody publishes the actual Ozempic rebate, so I can’t tell you whether it is small, enormous, or somewhere in between. That part is not settled by anything public.

The people who get hurt by this structure are the ones whose costs are computed off the list price: someone paying cash, or someone whose insurance has them pay a percentage of the drug’s price before or instead of a flat copay. For them the fictional number becomes quite real. The fiction is load-bearing for exactly the people who are not in the room.

What the other prices reveal about the list price

The best way to see that the sticker is mostly a negotiating position is to look at all the other prices the same company is willing to accept for the same molecule.

The Medicare price. Semaglutide was included in the second round of Medicare drug price negotiations under the Inflation Reduction Act, and the result is $274 per 30-day supply from January 1, 2027. DrugPatentWatch says this “represents a 71% reduction from the 2024 list price of $959.” Which is true arithmetically, and also a slightly funny way to put it, because it measures a real price against a list price, a bit like measuring your height against the tallest number on a ruler.

The direct-to-patient price. As of October 21, 2026, Disclosed Labs reports Novo Nordisk’s NovoCare Pharmacy self-pay price for Wegovy starts at $199 a month for the pen and $149 for the pill. Wegovy is semaglutide. The pen is a pen. The company, selling directly and skipping the middle, is willing to start at roughly a fifth of the Ozempic sticker.

The compounders’ price. When US compounding pharmacies were selling injectable semaglutide, they averaged about $230 a month, “more than half off the branded drug prices,” per MedPath. (That is another site’s beat, and a legal story more than a price story.) But it tells you the market had a guess about what the stuff is worth when nobody is printing a list.

If you line these up, $959 is the outlier, not the anchor. It is the MSRP on the window of the car, and everyone who has bought a car knows what the MSRP is for. It is for the salesperson to walk you down from.

What generics do to the sticker

The list price also exists because nobody else is allowed to sell semaglutide in the United States yet. The core compound patent runs to December 5, 2031 (exactly 14 years after Ozempic’s approval on December 5, 2017), and Novo Nordisk reports 2032 as the effective expiry. Apotex got the first FDA tentative approval for a generic Ozempic on April 10, 2026, which means approved-ish, pending the patents. Novo has settled litigation with seven would-be generic makers, and “all settlement terms are confidential,” which is the corporate version of what happened at the bachelor party staying at the bachelor party.

India is the preview. Over 40 generic semaglutide brands launched there on March 21, 2026, the day after the patent expired. About ten days later Novo cut Ozempic by 36% and Wegovy by 48%. Notice the speed. A list price that could drop a third in ten days was not, I suppose, a price the company needed in order to keep the lights on.

The US version will probably be gentler. One source says US biosimilar or generic peptide drugs typically get 15 to 40% price reductions, against the 80 to 90% common for ordinary pills, and when generic Victoza launched, Teva’s version was about 16 to 17% cheaper than the brand. FDA data show generics running about 39% below brand with one generic maker and more than 95% below with six or more. So the answer depends on how many show up, which is not settled.

Why the sticker number survives

It is worth asking why a company keeps a list price that its own other channels so cheerfully undercut. The honest answer is that the list price is useful to almost everyone who sets it. It is the base from which rebates are measured, the number that makes a discount look big, and the opening offer in every negotiation, including the government’s.

Price changes come with their own vocabulary, too. Eli Lilly raised the UK price of its rival drug Mounjaro, a move reported by Pharmaceutical Technology as meant to “better reflect market conditions.” Translated into flat English: we found out people would pay more, so now they will.

I write about drug prices for a living, which mostly means reading other people’s sentences about prices very slowly and then writing longer sentences about them. lol. It is a strange job. But the slow reading is the whole thing here, because the sentence everyone quotes is precise about exactly one thing: that it is a list price. Every other price in this article is lower. Most of them come from the same company.

The list price is the price you pay when nobody is negotiating for you.